Literature DB >> 26835544

Subclonality for BRAF Mutation in Papillary Thyroid Carcinoma Is Associated With Earlier Disease Stage.

Alona Finkel1, Lior Liba1, Einav Simon1, Tova Bick1, Elad Prinz1, Edmond Sabo1, Ofer Ben-Izhak1, Dov Hershkovitz1.   

Abstract

CONTEXT: The presence of driver mutations only in a subset of tumor cells within a single lesion, defined as subclonality, is being appreciated as a clinically significant factor. BRAF mutation is the most common driver mutation in papillary thyroid carcinoma (PTC). There are conflicting data in the literature regarding the presence of BRAF mutation subclonality in PTC and its clinical significance.
OBJECTIVE: The purpose of the present study was to use a molecular and morphometric approach to determine BRAF clonality status and its clinical-pathological correlates.
DESIGN: Fifty-nine cases of PTC were studied. DNA extracted from the tumors underwent deep sequencing to determine the percentage of BRAF mutant allele copies. Additionally, we used computerized morphometry to determine the fraction of tumor cells in each sample. Using both variables, we were able to determine the presence or absence of subclonality for BRAF mutation, which was further correlated with clinical, pathological, and prognostic data.
RESULTS: BRAF mutation was found in 49 (83%) cases. The average percentage of tumor cells and of BRAF mutant alleles in the samples were 68.1 ± 9.8 and 26 ± 6.7, respectively. Based on the molecular and morphometric analysis, 11 (24%) cases were found to be subclonal for BRAF mutation. Tumors with subclonal BRAF mutations were significantly smaller compared to tumors with clonal mutation (0.82 ± 0.38 cm vs 1.37 ± 0.57 cm, P = .005) and were less likely to have lymph node metastasis (0% vs 32%, P = .03).
CONCLUSIONS: In PTC, subclonality for BRAF mutation is associated with earlier stage. Molecular-morphometric analysis of PTC can provide clonality information with potential clinical significance.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26835544     DOI: 10.1210/jc.2015-4031

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  The micropapillary/hobnail variant of papillary thyroid carcinoma: A review of series described in the literature compared to a series from one southern Italy pathology institution.

Authors:  Antonio Ieni; Valeria Barresi; Roberta Cardia; Luana Licata; Flavia Di Bari; Salvatore Benvenga; Giovanni Tuccari
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

Review 2.  Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma.

Authors:  Xiaojing Wei; Xiaodong Wang; Jie Xiong; Chen Li; Yixuan Liao; Yongjun Zhu; Jingxin Mao
Journal:  Biomed Res Int       Date:  2022-05-18       Impact factor: 3.246

3.  Validation of molecular biomarkers for preoperative diagnostics of human papillary thyroid carcinoma in fine needle aspirates.

Authors:  Samira M Sadowski; Volodymyr Petrenko; Patrick Meyer; Marc Pusztaszeri; Marie-Claude Brulhart-Meynet; Mounia Heddad Masson; Frédéric Triponez; Jacques Philippe; Charna Dibner
Journal:  Gland Surg       Date:  2019-08

4.  Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.

Authors:  Young Jun Chai; Jin Wook Yi; Hyeon-Gun Jee; Young A Kim; Ju Han Kim; Mingzhao Xing; Kyu Eun Lee
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

5.  Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.

Authors:  Einav Simon; Tova Bick; Shada Sarji; Talia Shentzer; Elad Prinz; Liza Yehiam; Edmond Sabo; Ofer Ben-Izhak; Dov Hershkovitz
Journal:  Oncotarget       Date:  2017-07-11

6.  A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer.

Authors:  Hongzhi Ma; Ru Wang; Jugao Fang; Qi Zhong; Xiao Chen; Lizhen Hou; Ling Feng; Xiaohong Chen; Zhigang Huang; Huanhu Zhao
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

Review 7.  A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.

Authors:  Cristina Romei; Rossella Elisei
Journal:  Int J Mol Sci       Date:  2021-02-09       Impact factor: 5.923

8.  Tissue architecture delineates field cancerization in BRAFV600E-induced tumor development.

Authors:  Elin Schoultz; Ellen Johansson; Carmen Moccia; Iva Jakubikova; Naveen Ravi; Shawn Liang; Therese Carlsson; Mikael Montelius; Konrad Patyra; Jukka Kero; Kajsa Paulsson; Henrik Fagman; Martin O Bergo; Mikael Nilsson
Journal:  Dis Model Mech       Date:  2021-08-11       Impact factor: 5.758

Review 9.  Update on Fundamental Mechanisms of Thyroid Cancer.

Authors:  Alessandro Prete; Patricia Borges de Souza; Simona Censi; Marina Muzza; Nicole Nucci; Marialuisa Sponziello
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-13       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.